Volume 8 - Issue 5

Research Article Biomedical Science and Research Biomedical Science and Research CC by Creative Commons, CC-BY

Age-Related Features of Detectability of Xenobiotic Enzyme Gene Polymorphism in Pregnant Women with Fetal Growth Restriction Syndrome

*Corresponding author: Mavlyanova NN, Republican Specialized Scientific and Practical Medical Center of Obstetrics and Gynecology, Ministry of Health, Republic of Uzbekistan.

Received: March 18, 2020; Published: April 30, 2020

DOI: 10.34297/AJBSR.2020.08.001314

Keywords

Keywords: Bone fracture; Bone drilling and equipment Specialist; Knowledge transfer; Oil well drilling

Introduction

Fetal growth restriction syndrome (FGRS) is a clinical syndrome caused by morphological and functional changes in the placenta and penetrant by limit of the growth and development of the fetus, its hypoxia, that arise as a result of the combined reaction of the fetus and placenta to various disorders of the pregnant woman. This syndrome is based on pathological changes in the fetal and or uterin-placental complexes with a derangement of the compensatory-adaptive mechanisms at the molecular, cellular and tissue levels. In this case, the transport, trophic, endocrine, metabolic, antitoxic functions of the placenta underlying the pathology of the fetus and newborn are disordered [1-7]. The most significant risk factors of FGRS development include preeclampsia and a combination of pregnancy with extragenital pathology, accompanied by vascular damage. Various etiological factors, affecting at different stages of the development and functioning of the placenta, are ultimately involved in the general pathogenetic mechanism leading to the development of the fetal growth limit syndrome, one of the main manifestations of which is considered a violation of placental circulation - the main function of the placenta [8-16]. In this regard, the main direction in the study of the problem of FGLS, is the development of objective methods for prediction, preclinical diagnosis, optimal prevention and treatment, which can significantly reduce the frequency of FGLS, and its complications. Recently, special attention has been paid to studying the genes of xenobiotic biotransformation enzymes (XBEs), which are candidate genes for the formation of a predisposition to these pathologies, since their protein products interact with the environment, detoxifying or toxicizing foreign chemical compounds that enter the body, including also drugs [17-19]. However, they have not yet been sufficiently studied as genetic predisposition factors in fetal growth limit syndrome. According to the literature, these genes are a rather complex object of study due to a number of their specific features [11,14,20]. These are overlapping substrate specificity, inducibility and participation in the metabolism of endogenous compounds. But it is precisely these features of XBE that make it possible to assume that they can be genetic markers at all stages of the development of the disease from its initiation to the outcome and, accordingly, will make it possible to identify a predisposition, help in the early diagnosis of the disease, knowing the patient’s genotype, make a prognosis of the course of the disease, and choose the most suitable therapy.

Aim

The aim of our research was to study the detectability of allelic variants of gene polymorphism of xenobiotic biotransformation enzymes of pregnant women with fetal growth limit syndrome taking into account the age of the pregnant.

Materials and Research Methods

The object and subject of the study were pregnant women with fetal loss syndrome (FLS), DNA samples from patients and healthy donors, glutathione transferase genes GSTM1 (1p13.3), GSTT1 (22q11.2) and glutathione transferase gene GSTP1 (IIe 105 Val). The study included 143 pregnant women aged 19 to 34 years, observed at the clinic of Republican Specialized Scientific and Practical Medical Center for Obstetrics and Gynecology, Ministry of Health of the Republic of Uzbekistan (RSSPMCOG MH RUz). All pregnant women underwent general clinical, laboratory and functional studies according to the standard for diagnostics and therapy (2015). Molecular genetic testing of biomaterials (DNA) was carried out on the basis of the Department of Molecular Medicine and Cellular Technology Research Institute of Hematology and Blood Transfusion under the Ministry of Health of the Republic of Uzbekistan. The object and subject of the study were DNA samples of pregnant and healthy donors, glutathione transferase genes of the first phase - GSTM1 (1p13.3), GSTT1 (22q11.2) and the second phase - GSTP1 (IIe 105 Val). During genetic studies, the population control was used as a comparison group, which was represented by DNA samples (n=72) of conditionally healthy ones from the DNA bank of this department. DNA samples were isolated from peripheral blood lymphocytes in accordance with a modified methodology. The concentration and purity of the extracted DNA was evaluated by measuring the optical density of DNA-containing solutions at a wavelength of 260 and 280 nm against TE on a NanoDrop 2000 spectrophotometer (USA). Genotyping of GSTT1 and GSTM1 polymorphism was carried out by PCR on programmable thermal cyclers CG-1-96 Corbett Research (Australia) and 2720 Applied Biosystems (USA), using test systems of LLC Litekh (Russia), according to the manufacturer’s instructions.

The Results of the Study

Clinical, laboratory and functional studies have shown that among the 143 pregnant women examined, fetal growth limit syndrome was detected in 105, which amounted to 73.4%. According to the severity degree, I - the degree of severity was diagnosed in 35 (33.3%), II the degree in 48 (45.7%) and III degree in 22, which amounted to 20.9%, respectively. Information on gene sequences and primer structure was obtained taking into account the original literary source [1] and Gene Bank. The characteristics of the genetic marker and the sequence of synthesized oligoprimers are shown in Table 1. Molecular genetic studies of the glutathione transferase genes GSTM1 (1p13.3), GSTT1 (22q11.2) and IIe 105 Val of the GSTP1 xenobiotic enzyme gene in the blood of pregnant women with FGLS revealed the following features of the distribution of alleles (Table 2) and genotypes of GSTM1 and GSTP1 gene polymorphisms (Tables 3 & 4). As it can be seen from Table 3, in the main group of pregnant women with SPP, functional alleles of GSTM1 “+” were detected in 67.8% of cases (40), while deletion variants (non-functional) of GSTM1 (0/0) were detected in 32.2% (19) cases. Whereas, functional allelic variants of GSTT1 “+” genotypes were detected in 20.3% of cases, and deletion variants in 79.6% (47) cases, respectively.

Biomedical Science &, Research

Table 1: The sequence of oligonucleotide primers used for PCR.

Biomedical Science &, Research

Table 2: The sequence of oligonucleotide primers used for PCR.

Biomedical Science &, Research

Table 3: Distribution frequency of alleles and genotypes of del / del genes polymorphism of the GSTM1 and GSTT1 in pregnant and control groups.

Biomedical Science &, Research

Table 4: The distribution frequency of alleles and genotypes of polymorphism IIe 105 Val of the GSTP1 gene in groups of patients and control.

As the comparative analysis of the distribution frequencies of the alleles and genotypes of the IIe 105 Val polymorphism of the GSTP1 xenobiotic enzyme gene among 114 DNA samples in 57 pregnant women revealed the presence of the normal A allele and 64.1% of the G allele in 35.1% of cases. Whereas, in the control group, the frequency of occurrence of the mutant allele IIe 105 Val of the GSTP1 xenobiotic enzyme gene was 12.5%, which was 2.8 times lower in comparison to the main group (P <0.05). For a detailed assessment of the prognostic criterion for the significance of the polymorphism of the genotypes of xenobiotic enzymes GSTM1, GSTT1 and GSTP1 in the development of fetal loss syndrome in pregnant women, we analyzed the results of analyzes depending on the presence of fetal loss syndrome (FGLS) and without .

The results of the study showed, that pregnant women with FGLS, combined functionally defective genotypes GSTM10 / 0 + GSTT10 / 0 were found in 28.2% of cases (11 pregnant women with FLS) than in the II control group individuals (20.0%), which is 1.4 times higher than in this group. In the group of pregnant women with FGLS “functionally unfavorable” A / G genotypes of the GSTP1 gene was found in 63.04% (29) versus 27.3% [21] of pregnant women without FLS, which was 2.3 times higher than the indicators of this groups (P <0.05). It should be noted that unfavorable homozygous genotypes were detected only in the I - group of pregnant women with FLS, which amounted to 17.4%. As it follows from Table 5, the indicators of the level of specificity and sensitivity of the del / + polymorphism of the GSTT1 gene were SE = 0.8 and SP = 0.75, respectively, at significantly high values (OR = 11.7; 95% CI 5.132- 26.9). At the same time, the calculated AUC indicator demonstrates a high level of effectiveness for predicting the development of the disease, which indicates the possible independent effect of this polymorphism on the risk of pathology development [22-28]. The SE and SP indices of the combined variant of the del polymorphisms of the GSTM1 + GSTT1 genes deviate towards sensitivity and are equal to 0.86 and 0.43, respectively and the efficiency rating is 0.65. These indicators also show a rather significant level of prognostic value of combinations of unfavorable genotypes as a genetic marker for predicting the development of fetal loss syndrome (Figure 2). Then, studies of the expected and observed heterozygous frequencies of the IIe 105 Val polymorphism of the GSTP1 gene in pregnant women with FLS and without revealed distinctive features. A rather significant level of prognostic value of combinations of unfavorable genotypes as a genetic marker for predicting the development of fetal loss syndrome. Then, studies of the expected and observed heterozygous frequencies of the IIe 105 Val polymorphism of the GSTP1 gene in pregnant women with FLS and without revealed distinctive features. (Table 6).

Biomedical Science &, Research

Table 5: Predictive efficacy of the studied genetic markers.

Biomedical Science &, Research

Table 6: The difference between the expected and observed frequencies of heterozygosity of the IIe 105 Val polymorphism of the GSTP1 gene.

Biomedical Science &, Research

Figure 1: Statistical analysis of the results was carried out using the statistical software package “OpenEpi 2009, Version 2.3”. Note: GSTM1 and GSTT1 gene detection electrophoregram (459 bps - GSTT1 gene, 375 bps - β-globin, 213 bps - GSTM1)

Biomedical Science &, Research

Figure 2: Electrophoregram for the detection of polymorphism (A / G) of the gene mutation -1 glutathione-S-transferase P1 (rs--): K - Negative control; K + Positive control; 1,3,8,9 - wild genotype A/A; 2,4,5,6,7,10 - heterozygous genotype A/G;

As follows from the figure, the detectability of the association of heterozygous polymorphism of “functionally unfavorable” genotypes A / G IIe 105 Val of the GSTP1 gene was observed in all studied ages - 20–25 years old - in 9 out of 16 (56.3%) pregnant women, 26–30 years old 11 out of 21 (52.4%), 31-35 - 9 out of 14 (64.3%) and over 36 years old 3 out of 6, while homozygous G/G genotypes were found at the age of 20-25 and 26 -30 years- 6.3% and 4.7%, respectively, and at the age of 31-35 years - in 14.3% of cases. Thus, an analysis of the association of intergenic combinations of zero polymorphisms of the GSTM1 and GSTT1 genes (Figure 1) revealed that in the group of pregnant women with fetal loss syndrome, combinations of the homozygous del/del genotype responsible for a lower level of protein product synthesis are significantly more common.

The chance of developing pathology in the presence of this combination of the genotypic variant of del/del genes GSTM1 and GSTT1 significantly increases: up to 7.8 times more compared to other genotypes (χ2 = 12.4; P = 0.0004; OR = 7.8; 95% CI 2.146- 28.65). Whereas, the functionally unfavorable G allele of the GSTP1 gene 2.7 times statistically significantly prevailed in the studied chromosomes of pregnant women with FLS compared with pregnant women without FLS (χ2 = 4.6; P = 0.03; OR = 4.5; 95% CI1.061-19.5). Analysis of the results of molecular genetic studies shows that female individuals of the Uzbek population with combined zero genotypes of the xenobiotic enzymes GSTM1 and GSTT1 (Figure 3), as well as hetero/homozygous genotypes of the IIe 105 Val GSTP1 polymorphism, have a tendency to risk fetal loss syndrome (χ2 = 12.4; P = 0.0004; OR = 7.8; 95% CI 2.146-28.65). Thus, the combined null genotypes GSTM10/0 + GSTT10/0 of the xenobiotic enzyme genes GSTM1 and GSTT1, as well as hetero (G/A) / homozygous (G/G) genotypes of the IIe 105 Val polymorphism of the GSTP1 gene, are significant markers of an increased risk of loss syndrome fetus in Uzbekistan (P <0.05) [29-35]. Allele A and the functionally favorable genotype A/A IIe 105 Val of the GSTP1 gene are significant protective markers for the development of pathology (χ2 = 18.6; P <0.05; OR = 3.9; 95% CI 2.023-7.07). The results obtained indicate that the variants of polymorphisms of the GSTM10/0 + GSTТ10/0 genotypes of the GSTM1 and GSTТ1 genes, as well as the G/A IIe 105 Val genotypes of the GSTP1 gene, are significant prognostic criteria for the risk of fetal growth limit syndrome, which are caused by disorders of the detoxification process in the body in women during pregnancy.

Biomedical Science &, Research

Figure 3: Indicators of detectability of the association of polymorphism of genotypes IIe 105 Val of the GSTP1 gene in the group of pregnant women, taking into account age.

Conclusion

  1. An analysis of the association of intergenic combinations of zero polymorphisms of the GSTM1 and GSTT1 genes revealed that in the main group of patients, combinations of the homozygous del/del genotype responsible for a lower level of protein product synthesis are significantly more common. The chance of developing pathology in the presence of this combination of the genotypic variant of del/del genes GSTM1 and GSTT1 significantly increases: up to 7.8 times more compared to other genotypes (χ2 = 12.4; P = 0.0004; OR = 7.8; 95% CI 2.146-28.65). there was a slight increase in the frequency of combinations of the heterozygous genotype 0/0 / “+” of these genes in the patient group compared to the control group (60.9% and 52.7%, respectively; χ2 = 0.1; P = 0.3; OR = 1.4; 95% CI 0.697-2.82).
  2. When analyzing the frequency distribution of alleles and genotypes of this polymorphism in the group of pregnant with FLS, significant differences were found compared with the control group. The functionally unfavorable GST allele of the GSTP1 gene 2.7 times statistically significantly prevailed in the studied chromosomes of pregnant women with FLS compared with pregnant women without FLS (χ2 = 4.6; P = 0.03; OR = 4.5; 95% CI1.061-19.5).
  3. Thus, the G allele and hetero / homozygous genotypes of the IIe 105 Val polymorphism of the GSTP1 gene are significant markers of an increased risk of developing fetal loss syndrome in Uzbekistan (P <0.05). Allele A and the functionally favorable A / A genotype are significant protective markers for the development of pathology (χ2 = 18.6; P <0.05; OR = 3.9; 95% CI 2.023-7.07).
  4. Taking into account the age of pregnant women, the detection of “functionally unfavorable” genotypes A / G IIe 105 Val of the GSTP1 gene is observed in women in active reproductive ages - 20–25–36 years 6%, which represents the social significance of the problem.
  5. Based on the variants of the del/del genotypes of the GSTM1 and GSTT1 genes and G alleles of the GSTP1 gene, one can determine the prognosis of the risk of developing fetal loss syndrome, characterized by a violation of the detoxification process of the body during pregnancy.
  6. The data obtained allows us to predict the risk of developing fetal loss syndrome, taking into account the assessment of the nature of the detoxification of the body during pregnancy and can be recommended for widespread use of the diagnostic method in obstetric practice.

References